Ragusa F V, Passalacqua G, Gambardella R, Campanari S, Barbieri M M, Scordamaglia A, Canonica G W
Servizio di Allergologia e Fisiopatologia Respiratoria Ospedale Cartoni, Rome.
J Investig Allergol Clin Immunol. 1997 May-Jun;7(3):151-4.
The present retrospective study reviews our clinical experience with Subcutaneous immunotherapy (SIT) over a 10 year period (1981-1991), in order to assess both incidence and clinical features of nonfatal systemic reactions due to this treatment. 192,505 injections were globally administered to 2,206 outpatients, following the suggested precautionary guidelines. We observed 115 systemic reactions (5.2% of patients and 0.06% of injections) and no fatalities. The association asthma + urticaria was the most frequent reaction (67%), followed by asthma alone (22%). No risk factor related to age, gender, pollen season or manufacturer was observed. The occurrence of systemic reactions was highly frequent in asthmatic patients, but approximately 1/3 of the patients who presented reactions had never previously suffered from asthma. The largest part of the observed reactions occurred during the maintenance phase of treatment. Almost all adverse events occurred within 30 minutes after the injection and they were promptly controlled by routine therapy. We conclude that subcutaneous immunotherapy, if performed with careful compliance to good clinical practice rules, is a safe treatment for respiratory allergy.
本回顾性研究回顾了我们在10年期间（1981 - 1991年）皮下免疫疗法（SIT）的临床经验，以评估该治疗引起的非致命性全身反应的发生率和临床特征。按照建议的预防指南，共对2206名门诊患者进行了192,505次注射。我们观察到115例全身反应（占患者的5.2%，注射次数的0.06%），无死亡病例。哮喘 + 荨麻疹联合反应最为常见（67%），其次是单纯哮喘（22%）。未观察到与年龄、性别、花粉季节或制造商相关的危险因素。全身反应在哮喘患者中高发，但出现反应的患者中约有1/3既往从未患过哮喘。观察到的反应大部分发生在治疗的维持阶段。几乎所有不良事件都发生在注射后30分钟内，且通过常规治疗可迅速得到控制。我们得出结论，皮下免疫疗法若严格遵循良好临床实践规则进行操作，是一种治疗呼吸道过敏的安全疗法。
